Cargando…

Comparing the efficacy and safety of IL-17 inhibitors for treatment of moderate-to-severe psoriasis: a randomized double blind pilot study with a review of literature

INTRODUCTION: Psoriasis is a chronic skin disease in which interleukin-17A (IL-17A) has been found to play an important role. Commercially available anti-IL-17 drugs include brodalumab, ixekizumab (IXE), and secukinumab (SEC). AIM: To compare the safety and efficacy of IXE and SEC in patients with m...

Descripción completa

Detalles Bibliográficos
Autores principales:	AlMutairi, Nawaf, Eassa, Bayoumy Ibrahim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2020
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9880774/ https://www.ncbi.nlm.nih.gov/pubmed/36751540 http://dx.doi.org/10.5114/ada.2019.91496

Ejemplares similares

Single Blinded Left-to-Right Comparison Study of Excimer Laser Versus Pulsed Dye Laser for the Treatment of Nail Psoriasis
por: Al-Mutairi, Nawaf, et al.
Publicado: (2014)

New and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitors
por: Gaspari, Anthony A, et al.
Publicado: (2015)

Compositional Alteration of Gut Microbiota in Psoriasis Treated with IL-23 and IL-17 Inhibitors
por: Huang, Yu-Huei, et al.
Publicado: (2023)

Efficacy and Safety of Netakimab, A Novel Anti-IL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of A 54-Week Randomized Double-Blind Placebo-Controlled PLANETA Clinical Trial
por: Puig, Luís, et al.
Publicado: (2021)

Efficacy, Safety and Pharmacokinetics of IL-17 Monoclonal Antibody Injection (AK111) in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blinded, Placebo-Controlled Phase Ib Multidose Escalation Clinical Study
por: Jiang, Congjun, et al.
Publicado: (2022)

The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond
por: Brembilla, Nicolo Costantino, et al.
Publicado: (2018)

A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis
por: Campa, Molly, et al.
Publicado: (2015)

The Role of IL-17 Cytokines in Psoriasis
por: Mosca, Megan, et al.
Publicado: (2021)

Erratum to: A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis
por: Campa, Molly, et al.
Publicado: (2016)

Outcome of Loupe-Assisted Sub-inguinal Varicocelectomy in Infertile Men
por: Abdelrahman, Selim S., et al.
Publicado: (2012)

Drug survival of ixekizumab, TNF inhibitors, and other IL‐17 inhibitors in real‐world patients with psoriasis: The Corrona Psoriasis Registry
por: Lockshin, Benjamin, et al.
Publicado: (2021)

Safety of IL-23 p19 Inhibitors for the Treatment of Patients With Moderate-to-Severe Plaque Psoriasis: A Narrative Review
por: Blauvelt, Andrew, et al.
Publicado: (2023)

The contribution of IL-17 to the development of autoimmunity in psoriasis
por: Furue, Masutaka, et al.
Publicado: (2019)

Clinical efficacy and IL-17 targeting mechanism of Indigo naturalis as a topical agent in moderate psoriasis
por: Cheng, Hui-Man, et al.
Publicado: (2017)

IL-21 Induces an Imbalance of Th17/Treg Cells in Moderate-to-Severe Plaque Psoriasis Patients
por: Shi, Yuling, et al.
Publicado: (2019)

The effects of IL-17/IL-17R inhibitors on atherosclerosis in psoriasis and psoriatic arthritis: A protocol for systematic review and meta analysis
por: Liu, Ningyuan, et al.
Publicado: (2021)

Literature Overview of the IL-17 Inhibition from Psoriasis to COVID-19
por: Zou, Yulin, et al.
Publicado: (2021)

Increased IL17A, IFNG, and FOXP3 Transcripts in Moderate-Severe Psoriasis: A Major Influence Exerted by IL17A in Disease Severity
por: de Oliveira, Priscilla Stela Santana, et al.
Publicado: (2016)

Crohn’s disease exacerbated by IL-17 inhibitors in patients with psoriasis: a case report
por: Ju, Jingyi, et al.
Publicado: (2020)

Skin Mycobiome of Psoriasis Patients is Retained during Treatment with TNF and IL-17 Inhibitors
por: Koike, Yuta, et al.
Publicado: (2020)

IL-17A and TNF-α inhibitors induce multiple molecular changes in psoriasis
por: Dong, Qiang, et al.
Publicado: (2022)

Add‐on effect of PSORI‐CM01 to topical calcipotriol for moderate psoriasis vulgaris: A multi‐center, randomized, double‐blind pilot study
por: Parker, Shefton, et al.
Publicado: (2021)

Safety of selective IL‐23p19 inhibitors for the treatment of psoriasis
por: Crowley, J.J., et al.
Publicado: (2019)

Efficacy and Safety of HLX03, an Adalimumab Biosimilar, in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blind, Phase III Study
por: Cai, Lin, et al.
Publicado: (2021)

Clinical implications of intermittent Ramadan fasting on stable plaque psoriasis: a prospective observational study
por: Almutairi, Nawaf, et al.
Publicado: (2021)

Long‐term safety of risankizumab from 17 clinical trials in patients with moderate‐to‐severe plaque psoriasis
por: Gordon, K.B., et al.
Publicado: (2021)

First‐in‐human study demonstrating the safety and clinical efficacy of novel anti‐IL‐17A monoclonal antibody CJM112 in moderate to severe plaque psoriasis
por: Kaul, M., et al.
Publicado: (2021)

The Clinical Significance of Simultaneous IL-17A and IL-17F Blockade in Psoriasis Non-Responding to Anti-IL17A Therapy
por: Kokolakis, Georgios, et al.
Publicado: (2022)

IL-17 Pathway Members as Potential Biomarkers of Effective Systemic Treatment and Cardiovascular Disease in Patients with Moderate-to-Severe Psoriasis
por: Wang, Xing, et al.
Publicado: (2022)

Long‐term efficacy and safety of secukinumab in Japanese patients with moderate to severe plaque psoriasis: 3‐year results of a double‐blind extension study
por: Okubo, Yukari, et al.
Publicado: (2019)

Efficacy and safety of brodalumab in the Korean population for the treatment of moderate to severe plaque psoriasis: A randomized, phase III, double‐blind, placebo‐controlled study
por: Seo, Seong Jun, et al.
Publicado: (2020)

Topical nicotinamide in combination with calcipotriol for the treatment of mild to moderate psoriasis: A double-blind, randomized, comparative study
por: Siadat, Amir Hossein, et al.
Publicado: (2013)

Differentiation of IL-26(+) T(H)17 intermediates into IL-17A producers via epithelial crosstalk in psoriasis
por: Fries, Anissa, et al.
Publicado: (2023)

The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis
por: Blauvelt, Andrew, et al.
Publicado: (2018)

Role of IL-17 in plaque psoriasis: therapeutic potential of ixekizumab
por: Hanley, Tessa L, et al.
Publicado: (2017)

IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications
por: von Stebut, Esther, et al.
Publicado: (2020)

Secukinumab: The Anti-IL-17A Biologic for the Treatment of Psoriasis
por: Fargnoli, Maria Concetta
Publicado: (2019)

First‐in‐human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL‐17A and IL‐17F, in mild psoriasis
por: Glatt, Sophie, et al.
Publicado: (2017)

IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE)
por: Eyerich, Kilian, et al.
Publicado: (2021)

Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
por: Bai, Fan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_h12qtq4npt7f2cn5etts8errlu